KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

Employees

133

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	2,268.00 ¥	0.00%	2,700
09/26/09	2,268.00 ¥	0.00%	1,200
08/26/08	2,268.00 ¥	0.00%	600

Delayed Quote Japan Exchange

More quotes

Market Closed - Japan Exchange Other stock markets 12:00:00 10/06/2026 pm IST			5-day change	1st Jan Change
2,268.00 ^JPY	0.00%		0.00%	+78.44%

22/04	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
25/03	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI

Market Cap	113.55Cr 70.91L 61.11L 56.25L 52.76L 99.11L 67Cr 1Cr 6.65Cr 2.6Cr 33Cr 2.66Cr 2.6Cr	P/E Ratio 2009	3.96x	P/E Ratio 2010	13.8x
Enterprise Value	204.43Cr 1.28Cr 1.1Cr 1.01Cr 94.99L 1.78Cr 120.64Cr 1.8Cr 12Cr 4.68Cr 59Cr 4.79Cr 4.69Cr	EV / Sales 2009	0.43x	EV / Sales 2010	0.55x
Free-Float	3.88%	Yield 2009	2.68%	Yield 2010	2.38%

22/04	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
25/03	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI
09/02	Denka Company Limited proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders for ¥7.9 billion.	CI
09/02	Denka Unit Launches Tender Offer for Kainos Laboratories	MT
06/02	Denka Co Ltd - Will launch tender offer for Kainos shares	RE
18/24/18	Italian stationery maker FILA cuts stake in listed Indian unit DOMS	RE
14/22/14	KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	CI
25/22/25	KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	CI
26/21/26	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.	CI
26/21/26	KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.	CI
25/21/25	KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.	CI
25/21/25	KAINOS Laboratories, Inc. authorizes a Buyback Plan.	CI
26/20/26	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.	CI

Current month	+0.18%
1 month	-0.22%
3 months	-0.53%
6 months	+80.29%
Current year	+78.44%

KAINOS Laboratories, Inc. Share Price

Stocks

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Valuation: KAINOS Laboratories, Inc.

Chart: KAINOS Laboratories, Inc.

Latest news : KAINOS Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: KAINOS Laboratories, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 week	2,268	2,269
1 month	2,263	2,277
Current year	1,257	2,284
1 year	1,204	2,284
3 years	1,005	2,284
5 years	929	2,284
10 years	488	2,284

Manager	Title	Age	Since
Yukihiro Nagatsu PSD	President	66	01/04/2022
Tsukasa Hayashi ADM	Chief Administrative Officer	64	01/06/2016
Nobuaki Nakano PRN	Corporate Officer/Principal	62	01/07/2024

Director	Title	Age	Since
Yukihiro Nagatsu BRD	Director/Board Member	66	01/06/2014
Tsukasa Hayashi BRD	Director/Board Member	64	01/06/2014
Kenji Kikuchi BRD	Director/Board Member	74	01/06/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAINOS LABORATORIES, INC.	0.00%	0.00%	+83.79%	+121.70%	6.3Cr
GUARDANT HEALTH, INC.	+10.76%	+4.83%	+165.57%	+245.81%	1.75TCr
BIOMÉRIEUX	-0.44%	-7.41%	-44.07%	-26.54%	925.25Cr
LANTHEUS HOLDINGS, INC.	-1.49%	+4.31%	+34.06%	+16.16%	680.49Cr
CARIS LIFE SCIENCES, INC.	+1.31%	+12.70%	-	-	507.98Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.18%	-1.84%	-27.83%	-27.74%	506.01Cr
DIASORIN S.P.A.	+1.20%	-5.77%	-27.88%	-31.23%	408.08Cr
ANDON HEALTH CO., LTD.	+10.00%	-5.22%	+85.21%	+83.18%	376.59Cr
10X GENOMICS, INC.	+13.07%	+9.20%	+189.42%	-45.73%	366.14Cr
AUTOBIO DIAGNOSTICS CO., LTD.	+2.66%	+3.18%	-14.34%	-39.66%	263.97Cr
Average	+2.46%	+0.38%	+49.32%	+32.88%	578.61Cr
Weighted average by Cap.	+1.39%	+0.94%	+65.19%	+74.56%

	2009	2010
Net sales	359.49Cr 2.24Cr 1.93Cr 1.78Cr 1.67Cr 3.14Cr 212.14Cr 3.17Cr 21Cr 8.22Cr 103.89Cr 8.42Cr 8.25Cr	421.51Cr 2.63Cr 2.27Cr 2.09Cr 1.96Cr 3.68Cr 248.74Cr 3.72Cr 25Cr 9.64Cr 121.81Cr 9.88Cr 9.67Cr
Net income	17Cr 10.47L 9L 8L 8L 14.64L 9.9Cr 14.79L 98.21L 38.36L 4.85Cr 39.3L 38.47L	10Cr 6L 5L 5L 5L 9L 5.99Cr 9L 59.4L 23.2L 2.93Cr 23.77L 23.27L
Net Debt	89Cr 55.75L 48.05L 44.23L 41.49L 77.93L 53Cr 78.71L 5.23Cr 2.04Cr 26Cr 2.09Cr 2.05Cr	91Cr 56.75L 48.91L 45.01L 42.23L 79.32L 54Cr 80.12L 5.32Cr 2.08Cr 26Cr 2.13Cr 2.08Cr